Skip to main content

Table 1 Demographics1

From: Serum Müllerian inhibiting substance levels are lower in premenopausal women with breast precancer and cancer

  Benign Precancer Cancer
Mean ± SD
Sample size 8 8 14
Time from sample collection to analysis (years) 3.02 ± 1.04 4.19 ± 2.40 2.24 ± 0.49
Participant age 42.4 ± 3.3 45.5 ± 4.5 43.7 ± 4.4
Age at menarche 13.1 ± 1.2 12.6 ± 1.0 12.6 ± 1.6
BMI 30.7 ± 6.9 30.7 ± 10.0 27.4 ± 9.1
MIS (ng/mL) 1.07 ± 0.90 0.30 ± 0.50 0.58 ± 0.80
ln(MIS (ng/mL) -0.27 ± 0.93 -2.91 ± 2.24 -2.31 ± 2.55
Frequency (%)
1st degree relative with breast cancer 1 (12.5%) 3 (37.5%) 2 (14.3%)
Current OCP use 1 (12.5%) 0 (0%) 2 (14.3%)
History of OCP use 4 (50%) 6 (75%) 12 (85.7%)
  1. 1: Results for time to sample collection, participant age, age at menarche, body mass index (BMI), and mullerian inhibiting substance (MIS) are mean +/- standard deviation. Results for 1st degree relative with breast cancer, current and history of oral contraceptive pill (OCP) use are frequency (%).